Pay in 4 interest-free payments of $5.93 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
A mutant impaired in the major high-affinity sulfate transporter SULTR1;2 responsible for uptake in Arabidopsis roots was reported earlier to contain decreased amounts of glutathione 83 but our data indicate that sultr1;2 seedlings exposed to AITC have a WT-like response
L.SchneiterG.ChofflonM.FunakoshiH.NakamuraT.et al (2010)
Depending on the dosage, undesirable side effects could range from minor to severe
TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) final data, not preliminary TRIUMPH-1 confirmed (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes pivotal trial met all primary endpoints TRANSCEND-T2D-1 confirmed (June 2026): -2.0% HbA1c and 16.8% weight loss in type 2 diabetes patients a separate diabetes-specific Phase 3 program Filing timeline updated: Eli Lilly will submit a Biologics License Application (BLA) not an NDA, since retatrutide is a biologic expected Q1 2027 (shifted from the previously estimated Q4 2026) Availability updated: Retatrutide remains investigational
